Venture&Growth
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
Chroma Therapeutics discovers and develops novel small-molecule drugs for the treatment of common cancers and inflammatory disorders.
Gilde joined the company as one of its first investors. The company has since advanced its lead product Tosedostat®, for leukemia, to the final development stage. It has also built a product pipeline of new inflammation therapies using its proprietary cell accumulation approach, which targets the nucleus of a cell. In 2009 it began to partner with GlaxoSmithKline (GSK). Chroma Therapeutics is based in Oxford, UK.
More Chroma Therapeutics news
Chroma Therapeutics Advances Novel Targeted Agent towards Clinical Development; Receives Milestone
Chroma Therapeutics enters collaboration with Cell Therapeutics Inc
Chroma Therapeutics signs $1 billion deal with GlaxoSmithKline
Chroma Therapeutics completes £15 million Series D financing
CHROMA announces Positive Phase II Efficacy Data for Novel Cancer Therapy Tosedostat
Venture&Growth
Acacia Pharma
Belgian Therapeutics company commercializing supportive care products to treat side effects of medical procedures.

Venture&Growth
Volta Medical
French Healthtech company developing AI software solutions to assist in cardiac operations.

Venture&Growth
Proverum
Proverum is an Irish medical device company founded in 2016 as a spin-off from Trinity College Dublin, developing novel treatment solutions for patients with symptomatic benign prostatic hyperplasia (BPH). BPH is a highly prevalent condition impacting an estimated 14 million
